FDA Publishes Draft Guidance On Psychedelic Drug Research By Mike Curley
The U.S. Food and Drug Administration on Friday published a new draft guidance highlighting considerations researchers should take into account while investigating the use of psychedelic drugs like psilocybin for treatment of medical conditions like depression and post-traumatic stress disorder. 1 document attached https://www.law360.com/compliance/articles/1692241?nl_pk=e8718aa1-2adc-4c2d-8e21-50ac9491223a&utm_source=newsletter&utm_medium=email&utm_campaign=compliance&utm_content=2023-06-26&nlsidx=0&nlaidx=11
